Study to measure how well aspirin is able to reduce the number of platelets in the blood of patients with reactive thrombocytosis caused by pseudomyxoma peritonei (a rare form of cancer that affects the lining of the abdomen and pelvis)

A prospective observational study to measure platelet inhibition by aspirin administered for reactive thrombocytosis in Pseudomyxoma Peritonei patients

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN41194672

Enrollment

156

Registered

2023-02-02

Start date

2023-01-16

Completion date

Unknown

Last updated

2025-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pseudomyxoma peritonei Cancer

Interventions

An observational study using blood samples to measure aspirin resistance in post-operative PMP patients who have reactive thrombocytosis and are prescribed aspirin. Blood samples will be taken at bas

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients >18 years of age 2. Diagnosis of Pseudomyxoma Peritonei 3. Patients undergoing CRS and HIPEC 4. Post-operative platelet count of >1000 x 10^9/L

Exclusion criteria

Exclusion criteria: 1. Patients <18 years of age 2. Having CRS and HIPEC for other conditions apart from Pseudomyxoma Peritonei 3. Allergic to aspirin 4. On other antiplatelet or drugs that affect platelet function e.g. NSAIDs 5. Ischaemic vascular events, percutaneous coronary intervention, or coronary artery bypass within the last 12 months

Design outcomes

Primary

Measure	Time frame
Aspirin resistance measured at baseline, 4 hours post aspirin administration, day 1, day 3, day 5 and day 14 or day of discharge, which ever comes first using the VerifyNowTM.	—

Secondary

Measure	Time frame
Determine if there are any thromboembolic events at 60 days post-operatively via completion of a questionnaire.	—

Countries

England, United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026